ACE-031 1mg

ACE-031 1 mg (recombinant human ActRIIB-Fc; “ramatercept”) from Peptide Tech is a dimeric research-use-only (RUO) fusion protein consisting of the extracellular domain of Activin Receptor Type IIB (ACVR2B) fused to the human IgG1 Fc region. Supplied lyophilized with rigorous documentation and cold-chain integrity, ACE-031 is designed for in-vitro ligand-trap studies across the TGF-β/activin/myostatin axis, SMAD2/3 reporter workflows, and high-specificity binding/neutralization assays.

 

Specifications

Property	Details
Product	ACE-031 (ActRIIB-Fc), lyophilized protein
Content per Vial	1 mg
Chemical Name	Recombinant human Activin Receptor Type IIB extracellular domain fused to human IgG1 Fc (dimeric glycoprotein)
Synonyms	ActRIIB-Fc; ACVR2B-Fc; soluble ActRIIB; ramatercept
CAS Number	Not assigned (biologic fusion protein)
PubChem CID	No PubChem small-molecule record (protein biologic). See UniProt ACVR2B Q13705 and IgG1 Fc P01857.
Sequence / Architecture	Human ACVR2B extracellular domain (typ. Ser19–Thr134)–hinge–human IgG1 Fc (CH2–CH3). Exact construct boundaries and tags are provided on the lot-specific COA.
Molecular Weight	~100–110 kDa (dimer, non-reducing); ~50–60 kDa (monomer, reducing). Apparent mass varies with glycosylation.
Appearance	White to off-white lyophilized cake/powder
Purity / Identity	≥95% by SDS-PAGE; identity by intact MS/peptide mapping; SEC-HPLC profile per COA
Endotoxin	Per-lot value reported on COA (third-party U.S. lab)
Solubility / Buffer	Reconstitute in sterile water or PBS (pH 7.2–7.4) to 0.2–1.0 mg/mL. For long-term aliquots, include carrier (e.g., 0.1% BSA or 5–10% trehalose) per your SOP.
Container	3 mL Type I glass vial; butyl stopper; flip-off seal
Storage (lyophilized)	−20 °C long-term (desiccated, light-protected)
After Reconstitution	Aliquot immediately; store ≤−20 °C (preferably −80 °C for extended periods). Avoid repeated freeze–thaw.
Intended Use	Laboratory research only (RUO). Not for human or animal use.

Molecular Structure

No 2D PubChem structure is available for this Fc-fusion protein. For reference domain structures and constructs, see ACVR2B (UniProt Q13705) and IgG1 Fc (UniProt P01857), and fused receptor-trap structures (e.g., PDB 7MRZ).

Key Features of Peptide Tech

• Same-Day Shipping (Mon–Fri, on in-stock items)
• GMP-Aligned lyophilization, documentation & traceability
• USA-Made biologics
• 24/7 Support & Price Match Guarantee
• Batch QR for instant COA & chain-of-custody verification
• 3rd-Party U.S. Lab Testing — purity, quantity, endotoxin
• Cold-Chain Shipping — Always (no paid upgrade)
• Worldwide Shipping; all major payments accepted
• Text & Email order updates; 2-Day FedEx/UPS standard with low-cost overnight
• Largest Variety of peptides, proteins & bioregulators

Potential Applications in Research (RUO)

Strictly for in-vitro, cell-based, or biochemical experiments. No health, diagnostic, or therapeutic claims.

• Ligand-trap & neutralization assays — quantify sequestration of myostatin (GDF-8), activin A, GDF11, and related ligands using ELISA/biochemical readouts or SMAD2/3 phosphorylation endpoints in responsive cell lines. Review context; decoy receptor background.
• SMAD reporter workflows — run luciferase reporters (CAGA-luc/SMAD2-3) to profile concentration-dependent inhibition of activin/myostatin signaling by ActRIIB-Fc in defined media. Pathway overview.
• BLI/SPR binding kinetics — determine on/off-rates and apparent affinities for ligand panels with immobilized ACE-031 or ligands; compare to published ActRIIB-Fc kinetics. Kinetic characterization.
• Endothelial/BMP9-10 pathway studies — interrogate BMP9/10-dependent signaling and its attenuation in endothelial models where type-II receptor engagement is required. Ligand-trap structures.
• Analytical method development — establish SEC-HPLC, SDS-PAGE, intact-MS/peptide-mapping, and endotoxin assays for Fc-fusion biologics; verify stability across buffers, pH, and temperatures (forced-degradation).

Citations (MLA)

1. Lee, Sangmin J., and Glenn A. Walter. “Targeting the Myostatin Signaling Pathway to Treat Muscle Loss.” Journal of Clinical Investigation, vol. 131, no. 10, 2021. https://www.jci.org/articles/view/148372.
2. Zimmerman, Christopher M., et al. “Characterization of the Ligand Binding Functionality of the Activin Receptor Type IIB Using a Soluble ActRIIB-Fc Chimera.” Journal of Biological Chemistry, 2009. Link.
3. Eguchi, Junichi, et al. “A Decoy Receptor (ACVR2B/Fc) Potently Inhibits Myostatin/Activin Signaling.” Proceedings of the National Academy of Sciences, 2020. PDF.
4. Nickerson, Jennifer L., et al. “Structures of Activin Ligand Traps Using Natural Sets of Type I and Type II TGF-β Receptors.” iScience, vol. 25, no. 2, 2022. Link.
5. UniProt Consortium. “ACVR2B — Activin Receptor Type-2B (Human).” UniProtKB (Q13705). Link.

Quality, Storage & Handling

Every lot is accompanied by a COA confirming purity (SDS-PAGE/SEC-HPLC), identity (MS/peptide-mapping), and endotoxin testing by independent U.S. labs. The on-vial QR links directly to batch documentation.

• Reconstitution: Bring to room temperature; add sterile water or PBS gently to the vial wall. Avoid vigorous vortexing; invert or swirl to dissolve. Filter (0.22 µm) if your SOP requires sterility.
• Stabilizers: For storage beyond 24–48 h in solution, prepare single-use aliquots with carrier (e.g., 0.1% BSA or 5–10% trehalose) and freeze promptly.
• Controls: Include ligand-only, isotype Fc, and dose-response controls for unambiguous pathway interpretation.

Shipping & Fulfillment

Ships with validated cold-chain packaging. In-stock orders placed before the daily cutoff ship the same day. 2-Day FedEx/UPS is standard, with overnight options available. Automated text/email updates included; international shipping available where permitted.

Compliance & RUO Disclaimer

For laboratory research only. Not a drug, cosmetic, food, or household chemical. Not for human or animal use, ingestion, diagnostic, or therapeutic applications. Purchasers warrant appropriate qualifications and compliance with applicable regulations and institutional policies.

FAQs

Is ACE-031 a peptide?

No. ACE-031 is a recombinant Fc-fusion protein (ActRIIB extracellular domain fused to human IgG1 Fc), not a short peptide.

Do you provide a PubChem structure image?

PubChem does not host a 2D structure for this biologic. See domain references on UniProt (ACVR2B Q13705; IgG1 Fc P01857) and fused-trap structures (e.g., PDB 7MRZ) linked above.

What purity and testing do you provide?

Each 1 mg vial is confirmed by SDS-PAGE/SEC-HPLC with MS/peptide-mapping identity; endotoxin testing is performed by third-party U.S. labs (see COA via on-vial QR).

How should I store reconstituted ACE-031?

Prepare single-use aliquots; store at ≤−20 °C (preferably −80 °C) and avoid repeat freeze–thaw. Include stabilizer per your SOP.

Explore More

Browse additional peptides, proteins, and accessories at Peptide Tech.

Related Products

• NAD+ 500mg
• Oxytocin 5mg
• PE-22-28 10mg
• PEG-MGF 2mg

Browse more in Peptides.

Always read the label and use products as directed. Consult a qualified professional where appropriate.